Tokio Marine Asset Management Co. Ltd. decreased its position in Thermo Fisher Scientific Inc. (NYSE:TMO) by 2.3% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 11,859 shares of the company’s stock after selling 274 shares during the period. Tokio Marine Asset Management Co. Ltd.’s holdings in Thermo Fisher Scientific were worth $1,752,000 at the end of the most recent reporting period.
Other hedge funds have also made changes to their positions in the company. Bank of Montreal Can acquired a new stake in shares of Thermo Fisher Scientific during the second quarter worth about $32,053,000. Bellevue Group AG acquired a new stake in shares of Thermo Fisher Scientific during the first quarter worth about $2,832,000. Artemis Investment Management LLP raised its stake in shares of Thermo Fisher Scientific by 54.6% in the second quarter. Artemis Investment Management LLP now owns 172,789 shares of the company’s stock worth $25,530,000 after buying an additional 61,046 shares during the last quarter. Puplava Financial Services Inc. raised its stake in shares of Thermo Fisher Scientific by 0.8% in the second quarter. Puplava Financial Services Inc. now owns 8,819 shares of the company’s stock worth $1,303,000 after buying an additional 71 shares during the last quarter. Finally, Lodestar Investment Counsel LLC IL raised its stake in shares of Thermo Fisher Scientific by 4.0% in the second quarter. Lodestar Investment Counsel LLC IL now owns 57,110 shares of the company’s stock worth $8,439,000 after buying an additional 2,180 shares during the last quarter. 87.38% of the stock is currently owned by institutional investors and hedge funds.
Shares of Thermo Fisher Scientific Inc. (NYSE:TMO) traded up 1.92% during trading on Friday, reaching $159.06. The company’s stock had a trading volume of 1,985,937 shares. The company’s 50-day moving average is $152.83 and its 200-day moving average is $149.86. The company has a market capitalization of $62.71 billion, a P/E ratio of 31.82 and a beta of 1.00. Thermo Fisher Scientific Inc. has a 12 month low of $119.75 and a 12 month high of $160.68.
Thermo Fisher Scientific (NYSE:TMO) last released its earnings results on Thursday, July 28th. The company reported $2.03 earnings per share for the quarter, topping analysts’ consensus estimates of $2.01 by $0.02. Thermo Fisher Scientific had a return on equity of 14.70% and a net margin of 11.35%. The business had revenue of $4.54 billion for the quarter, compared to the consensus estimate of $4.50 billion. During the same period last year, the business earned $1.84 earnings per share. The firm’s revenue for the quarter was up 6.2% compared to the same quarter last year. On average, analysts forecast that Thermo Fisher Scientific Inc. will post $8.17 EPS for the current fiscal year.
The company also recently announced a quarterly dividend, which will be paid on Monday, October 17th. Investors of record on Thursday, September 15th will be given a dividend of $0.15 per share. This represents a $0.60 dividend on an annualized basis and a yield of 0.38%. The ex-dividend date of this dividend is Tuesday, September 13th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is presently 12.02%.
A number of analysts have recently issued reports on TMO shares. Cleveland Research lowered Thermo Fisher Scientific from a “buy” rating to a “neutral” rating in a research report on Friday, September 9th. JPMorgan Chase & Co. initiated coverage on Thermo Fisher Scientific in a report on Thursday, September 22nd. They issued an “overweight” rating and a $180.00 price objective for the company. Zacks Investment Research raised Thermo Fisher Scientific from a “hold” rating to a “buy” rating and set a $175.00 price objective for the company in a report on Wednesday, July 20th. Citigroup Inc. boosted their price objective on Thermo Fisher Scientific from $160.00 to $182.00 and gave the company a “buy” rating in a report on Friday, July 29th. Finally, Mizuho set a $175.00 price objective on Thermo Fisher Scientific and gave the company a “buy” rating in a report on Thursday, July 28th. Three investment analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus price target of $160.79.
In other Thermo Fisher Scientific news, VP Seth H. Hoogasian sold 5,023 shares of Thermo Fisher Scientific stock in a transaction that occurred on Wednesday, August 10th. The stock was sold at an average price of $156.00, for a total transaction of $783,588.00. Following the sale, the vice president now directly owns 31,914 shares of the company’s stock, valued at $4,978,584. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Marc N. Casper sold 28,797 shares of Thermo Fisher Scientific stock in a transaction that occurred on Friday, September 2nd. The shares were sold at an average price of $151.01, for a total value of $4,348,634.97. Following the sale, the chief executive officer now directly owns 307,444 shares in the company, valued at $46,427,118.44. The disclosure for this sale can be found here. Corporate insiders own 0.52% of the company’s stock.
Thermo Fisher Scientific Company Profile
Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company is a provider of analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. The company operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.
Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO).
Receive News & Ratings for Thermo Fisher Scientific Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific Inc. and related companies with MarketBeat.com's FREE daily email newsletter.